Antiangiogenic therapy in malignant gliomas
Authors:
- Andrew D NordenANAndrew D Norden
- Jan DrappatzJDJan Drappatz
- Patrick Y WenPWPatrick Y Wen
- 1 November 2008
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 20 (6) , 652-661
Abstract
Antiangiogenic drugs are increasingly used in malignant glioma therapy. This article reviews the rationale for targeting angiogenesis in malignant gliomas, summarizes relevant clinical trial results, and discusses promising avenues of investigation in antiangiogenic therapy. Combination therapy with bevacizumab, the humanized monoclonal antibody against vascular endothelial growth factor, and irinotecan has emerged as the treatment of choice for recurrent malignant gliomas, prolonging progression-free survival markedly in comparison with historical controls. Several small molecule tyrosine kinase inhibitors of the vascular endothelial growth factor receptor are under investigation and show promise as well. Antiangiogenic treatments are effective and well tolerated options for recurrent malignant glioma. Future studies will determine whether these drugs have a role in first line therapy. Studies are in progress to elucidate mechanisms of resistance and suggest approaches to further improve survival in patients with these challenging tumors.Keywords
This publication has 70 references indexed in Scilit:
- Bevacizumab/Irinotecan. Un nouveau traitement actif dans les gliomes de haut grade récidivants : résultats préliminaires d’une étude multicentrique de l’AnocefRevue Neurologique, 2008
- HIF1α Induces the Recruitment of Bone Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and InvasionCancer Cell, 2008
- Antiangiogenics: The Potential Role of Integrating This Novel Treatment Modality With Chemoradiation for Solid CancersJournal of Clinical Oncology, 2007
- Anticancer Therapies Combining Antiangiogenic and Tumor Cell Cytotoxic Effects Reduce the Tumor Stem-Like Cell Fraction in Glioma Xenograft TumorsCancer Research, 2007
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007
- Glioma stem cells promote radioresistance by preferential activation of the DNA damage responseNature, 2006
- Stem Cell–like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth FactorCancer Research, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseBritish Journal of Cancer, 2000
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994